J&J sees AI halving the time to generate drug development leads
- 2 days ago
- 1 min read
REUTERS — Discovering new products outright and bringing them to market using AI is not yet possible, but J&J is using the new technology to screen the "potential universe" for promising chemical compounds or biologics, CIO Jim Swanson said at the Reuters Momentum AI event in New York.
"That's still a ways away, but we can optimize," Swanson said. "We've cut our lead optimization time in half."
Read the full story | REUTERS
